Flagyl and Depakene drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Flagyl (metronidazole) and Depakene (valproic acid). Common drug interactions include abdominal pain upper among females and confusional state among males.

The phase IV clinical study analyzes what interactions people have when they take Flagyl and Depakene. It is created by eHealthMe based on reports of 48 people who take the same drugs from the FDA, and is updated regularly.

What is Flagyl?

Flagyl has active ingredients of metronidazole. It is often used in vaginitis bacterial. eHealthMe is studying from 25,897 Flagyl users. Check the latest studies of Flagyl.

What is Depakene?

Depakene has active ingredients of valproic acid. It is often used in epilepsy. eHealthMe is studying from 14,776 Depakene users. Check the latest studies of Depakene.



On Jul, 07, 2026

48 people who take Flagyl and Depakene together, and have interactions are studied.

Flagyl and Depakene drug interactions.

What are the common drug interactions of Flagyl and Depakene, by gender? *:

female:

  1. Abdominal pain upper
  2. Aortic rupture
  3. Blood creatine phosphokinase increased
  4. Blood creatinine increased
  5. Bone marrow failure
  6. Brain abscess
  7. Candida sepsis (candida in blood stream)
  8. Cholestasis (a condition where bile cannot flow from the liver to the duodenum)
  9. Compression fracture (fracture due to pressure caused by injury)
  10. Convulsions (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled of muscles contract and relax rapidly and repeatedly)

male:

  1. Confusional state
  2. Headache (pain in head)
  3. Respiratory arrest (cessation of normal respiration due to failure of the lungs to function effectively)
  4. Arrhythmia (irregular heartbeat)
  5. Epistaxis (bleed from the nose)
  6. Erythema (redness of the skin)
  7. Gingival bleeding (bleeding gums)
  8. Haemorrhage subcutaneous (bleeding from skin)
  9. Idiopathic thrombocytopenic purpura (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting)
  10. Nasopharyngitis (inflammation of the nasopharynx)

What are the common drug interactions of Flagyl and Depakene, by age (0-1 to 60+)? *:

0-1:

  1. Brain damage
  2. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)

2-9:

  1. Drug ineffective
  2. Increased bronchial secretion
  3. Arrhythmia (irregular heartbeat)
  4. Epistaxis (bleed from the nose)
  5. Gingival bleeding (bleeding gums)
  6. Haemorrhage subcutaneous (bleeding from skin)
  7. Idiopathic thrombocytopenic purpura (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting)
  8. Platelet disorder
  9. Pneumonia
  10. Pulmonary haemorrhage (acute bleeding from the lung)

10-19:

  1. Encephalopathy (functioning of the brain is affected by some agent or condition)
  2. Erythema (redness of the skin)
  3. Nasopharyngitis (inflammation of the nasopharynx)
  4. Pruritus (severe itching of the skin)
  5. Sinus congestion (blockage of sinus)
  6. Sinusitis (inflammation of sinus)
  7. Wound

20-29:

  1. Respiratory arrest (cessation of normal respiration due to failure of the lungs to function effectively)

30-39:

  1. Splenic necrosis (death of most or all of the cells of spleen)
  2. Splenic vein thrombosis (blood clot in splenic vein)
  3. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  4. Tachypnoea (a condition of rapid breathing over 20 per minute)
  5. Haematocrit decreased
  6. Infection
  7. Feeling cold
  8. Haemoglobin decreased
  9. Laboratory test abnormal
  10. Neutropenia (an abnormally low number of neutrophils)

40-49:

  1. Confusional state
  2. Headache (pain in head)
  3. Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system)
  4. Renal failure acute (rapid kidney dysfunction)
  5. Blood potassium increased
  6. Hepatitis acute
  7. Hepatocellular damage (liver damage)
  8. Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)
  9. Radiculopathy (a set of conditions in which one or more nerves is affected and does not work properly)

50-59:

  1. Hypoaesthesia (reduced sense of touch or sensation)
  2. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  3. Thrombocytopenia (decrease of platelets in blood)
  4. Tremor (trembling or shaking movements in one or more parts of your body)

60+:

  1. Status epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure)
  2. Drug level increased
  3. Oedema (fluid collection in tissue)
  4. Polyneuropathy (neurological disorder that occurs when many peripheral nerves throughout the body malfunction simultaneously)
  5. Posterior reversible encephalopathy syndrome (posterior reversible encephalopathy syndrome (pres), also known as reversible posterior leukoencephalopathy syndrome (rpls), is a syndrome characterized by headache, confusion, seizures and visual loss)
  6. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
  7. Sepsis (a severe blood infection that can lead to organ failure and death)
  8. Subarachnoid haemorrhage (blood leaks into the space between two membranes that surround the brain)
  9. Toxic encephalopathy (a degenerative neurologic disorder caused by exposure to toxic substances)
  10. Abdominal pain upper

What are the existing conditions these people have? *

  1. Gastric Ulcer (stomach ulcer): 4 people, 8.33%
  2. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 4 people, 8.33%
  3. Insomnia (sleeplessness): 3 people, 6.25%
  4. Infection: 3 people, 6.25%
  5. Diverticular Perforation (serious gastrointestinal condition in which the intestine's walls are perforated): 3 people, 6.25%
  6. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 3 people, 6.25%
  7. Brain Neoplasm Malignant (brain cancer tumour): 3 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Flagyl and Depakene?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Flagyl and Depakene:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Flagyl:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Depakene:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Flagyl and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Depakene and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on metronidazole and valproic acid (the active ingredients of Flagyl and Depakene, respectively), and Flagyl and Depakene (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: